Navigation Links
Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
Date:6/16/2008

Results presented at the 90th annual Endocrine Society meeting show significant improvements among women affected by moderate to severe vaginal

dryness and painful intercourse

ANN ARBOR, Mich, June 16 /PRNewswire/ -- QuatRx Pharmaceuticals today announced detailed primary endpoint results from a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women with symptoms of vulvovaginal atrophy, a common condition associated with menopause. The study successfully met all four co-primary endpoints. Women treated with Ophena(TM) at the 60 mg dose showed statistically significant improvements in vaginal dryness and dyspareunia (painful intercourse), as well as statistically significant improvement in the proportion of parabasal and superficial cells in the epithelium of vaginal walls and a decline in vaginal pH levels. Results of this Phase 3 clinical trial were presented today in a poster presentation at the 90th annual Endocrine Society meeting in San Francisco.

The decline in estrogen levels in women after menopause is associated with an increase in vaginal pH levels as well as a thinning of the vaginal wall, resulting in bothersome symptoms such as vaginal dryness and painful intercourse. In the Phase 3 Ophena(TM) clinical study, women were asked to identify their most bothersome symptom of vaginal atrophy. The co-primary endpoints were defined as the change from baseline to week 12 in the percentage of parabasal cells in the vaginal maturation index, the percentage of superficial cells in the vaginal maturation index, vaginal pH, and improvements in the most bothersome moderate to severe vulvovaginal atrophy symptom.

"Vaginal atrophy symptoms in postmenopausal women are usually progressive and, unlike hot flashes, do not resolve spontaneously. They can have a significant impact on a woman's quality of life. These Phase 3 clinical study results indicate that this new oral tablet ha
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
6. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
11. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014  Vermillion, ... company focused on gynecologic cancers and women,s health, has ... of Sales and Managed Markets. Ms. Bauzon ... traction and expanding payer coverage for laboratory services companies. ... most recently with PerkinElmer, Inc., where she held the ...
(Date:8/21/2014)... -- Publicis Groupe customer engagement agency Rosetta today ... Industry Group Leader, has been featured in the 2014 ... people in the life-sciences industry. Those chosen for this ... technology, creativity, strategy and medicine. Hartley ... its leading Rosetta Consulting practice. In 2012, she was ...
(Date:8/21/2014)... /PRNewswire-iReach/ -- Inc. magazine today ranked ... straight year, No. 349 in Health on its ... the nation,s fastest-growing private companies. The list represents ... segment of the economy—America,s independent entrepreneurs. Companies such ... Zillow, and many other well-known names gained early ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:8/22/2014)... Jose, CA (PRWEB) August 22, 2014 ... now offering a new teeth whitening technique. Air polishing ... regular cleaning appointments. , Dark teeth can be caused ... two categories: external stains and internal stains. External stains ... stains can be caused by certain medications, such as ...
(Date:8/22/2014)... 23, 2014 Recently, iFitDress.com, a well-known ... collection of discounted wedding gowns . In addition ... all these new products are provided with low shipping ... happy to unveil the new wedding gowns. In our ... gowns for ladies to choose from. What’s more, all ...
(Date:8/22/2014)... Amy Norton HealthDay Reporter ... A growing number of Americans on work disability chronically ... Researchers found that between 2007 and 2011, about ... benefits were prescribed narcotic painkillers each year. And the ... in 2007 to 23 percent in 2011. ...
(Date:8/22/2014)... LSU Health New Orleans School of Nursing was ... to increase access to advanced nursing education and ... as well as veterans. The Health Resources and ... and Human Services awarded the two-year grant. Scharalda ... project director., The Advanced Education Nursing Traineeship (AENT) ...
(Date:8/22/2014)... August 22, 2014 As the ... http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues to grow, ... companies have decided to limit coverage of uterine ... Telegram, Blue Cross-Blue Shield of Massachusetts will no ... involve morcellation as of September 1, 2014. Other ...
Breaking Medicine News(10 mins):Health News:Japantown Dental Introduces Air Polishing 2Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... China, May 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc., ... "Company"),(which recently changed its name from Genesis ... U.S. pharmaceutical company with its,principal operations in ... today,that its management will present at the ...
... Online Resource, YouCanBeTheOne.com, Recommended to Help Guide Important Conversations ... YORK, May 12 The multi-disciplinary expert consortium known ... calling upon family and friends to proactively start a ... physician at the first sign of possible Alzheimer,s disease ...
... Commissioned by Non-Profit Identifies Unmet Needs of CaregiversWASHINGTON, May ... Wellness Community revealed many Americans who provide support to ... as a caregiver. In fact, only 20 percent ... estimate of 60 percent. This year, it is projected ...
... and Pharma on PanelWALTHAM, Mass., May 12 ... ) announced today that CEO Lewis H. Bender will ... Markers in Drug Development: How Personalized Medicine is Evolving ... May 18-21, 2009 in Atlanta, GA. The panel ...
... DOYLESTOWN, Pa., May 12 The Quigley Corporation (Nasdaq: ... today announced that the world,s leading independent proxy advisory ... Glass Lewis & Co. have recommended that stockholders vote ... investor Ted Karkus, solicitation seeking control of the Board ...
Cached Medicine News:Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 2Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 4Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 5Health News:Cancer Caregiver Distress Unrecognized and Under Reported 2Health News:Cancer Caregiver Distress Unrecognized and Under Reported 3Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 2Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 2Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 4
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
... of septicemia occur yearly in the U.S., ... of the organism and the determination of ... The Wampole ISOSTAT/ ISOLATOR Microbial System is ... centrifugation. This technology is used to concentrate ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
Medicine Products: